EMR three-lens brief
Evidence-based stock research on EMR. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Analyst mean target $164.32 — 18% above current (27 analysts).
- Analyst mean target $164.32 — 18% above current (27 analysts).
- Earnings scheduled 2026-08-05.
EMR closed at $139.16 (+0.99%) as of 2026-07-10. Market cap: $77.94B. P/E (trailing) 32.3. Price is below the 50-day MA and above the 200-day MA. Positives: analyst mean target $164.32 — 18% above current (27 analysts).. Last quarter: Revenue $4.56B, net income $618.00M, free cash flow $3.27B. Watching for: 2026-08-05 earnings release (25 days out).
Why three lenses on EMR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine EMRacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/EMR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath EMR brief"></iframe>